The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE4
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
- Status
- TERMINATED
- Phase
- PHASE2
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- Status
- WITHDRAWN
- Phase
- PHASE1
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2